The 11 Wall Street analysts covering SAB Biotherapeutics, Inc. hold a median 12-month price target of $12 — +271.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 28 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores SAB Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (74): The shares have been drifting up relative to others.
Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SABS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +271.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 June 2026 | Barclays | Initiates | Overweight | $13 |
| 17 June 2026 | Chardan Capital | Maintains | Buy | $14 → $16 |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 June 2026 | Leerink Partners | Maintains | Outperform | — |
| 22 May 2026 | Citigroup | Initiates | Buy | — |
| 20 May 2026 | Jefferies | Initiates | Buy | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 May 2026 | Rodman & Renshaw | Reiterates | Buy | — |
| 2 Apr 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 11 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Jan 2026 | UBS | Initiates | Buy | — |
| 19 Dec 2025 | Guggenheim | Initiates | Buy | — |
| 18 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 19 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Sept 2025 | Leerink Partners | Initiates | Outperform | — |
| 8 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 22 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 May 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SABS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, SAB Biotherapeutics, Inc. returned +6.3% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 63% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 35% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SAB Biotherapeutics, Inc. has a market value of $291.2M and an enterprise value of $193.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.8M.
Free cash flow in the twelve months to 30 June 2026: −$57.4M.
Trailing P/E: 12.4×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
SAB Biotherapeutics, Inc. employs 86 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SAB Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SAB Biotherapeutics said it will release third-quarter 2026 financial results on the morning of November 5 and hold a conference call and webcast at 8:30 a.m. ET to discuss the results and provide business updates.
Why it matters — SABS watchers can follow the scheduled call for the company’s quarterly results and business updates.
Executives from Healios and SAB Biotherapeutics outlined their approaches to developing scalable biologic therapies during a Chardan discussion focused on treatments designed for commercial manufacturing.
Why it matters — The discussion highlighted SABS’s approach to scalable biologic development and its human antibody platform, topics relevant to the company’s development strategy.
SAB Biotherapeutics said members of its management team will participate in the Chardan 10th Annual Healthcare Conference on October 20, 2026. The event is scheduled as a fireside chat from 11:15 to 11:30 a.m. ET, with Samuel J. listed as presenter.
Why it matters — SABS watchers may note the scheduled management appearance and its opportunity to discuss the company at the healthcare conference.
SAB BIO received FDA Fast Track designation for SAB-142 in Stage 3 type 1 diabetes. The designation recognizes the candidate’s potential to address an unmet medical need for people with the condition.
Why it matters — The FDA designation is a development update for SABS’s SAB-142 program targeting Stage 3 type 1 diabetes.
SAB Biotherapeutics announced it will present encore Phase 1 data for SAB-142, its fully human anti-thymocyte immunoglobulin for type 1 diabetes, at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026), held October 9-11, 2026, in Philadelphia, PA.
Why it matters — A SABS watcher would care because presenting SAB-142 data at a dedicated T1D congress raises visibility of the company's lead candidate among the type 1 diabetes community.
The 11 Wall Street analysts covering SAB Biotherapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering SAB Biotherapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SAB Biotherapeutics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, SAB Biotherapeutics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (74 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +271.5% from the last close, and Ticker Nerd's factor model ranks SAB Biotherapeutics, Inc. 41 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering SAB Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SABS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.
SAB Biotherapeutics, Inc. returned +6.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET". SAB Biotherapeutics said it will release third-quarter 2026 financial results on the morning of November 5 and hold a conference call and webcast at 8:30 a.m. ET to discuss the results and provide business updates.
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases. The company’s platform is designed to produce high-potency antibody therapies without relying on human donors or convalescent plasma, using a proprietary approach to generate targeted immunoglobulins. Its current pipeline is centered on SAB-142, a lead product candidate being developed for autoimmune type 1 diabetes. SAB Biotherapeutics Inc. also applies its DiversitAb platform to create multi-target antibody medicines intended for difficult-to-treat conditions across immunology and infectious disease. Based in the United States, the company operates in the biotechnology sector, where it contributes to the development of next-generation antibody-based treatments for patients with significant unmet medical needs.
CEO Mr. Samuel J. Reich · 86 employees · United States · https://www.sab.bio
